MARKET

MRNA

MRNA

Moderna
NASDAQ
29.46
-0.17
-0.57%
Pre Market: 29.39 -0.07 -0.24% 09:06 12/15 EST
OPEN
29.46
PREV CLOSE
29.63
HIGH
30.44
LOW
29.40
VOLUME
14.63K
TURNOVER
--
52 WEEK HIGH
48.92
52 WEEK LOW
22.28
MARKET CAP
11.51B
P/E (TTM)
-3.6602
1D
5D
1M
3M
1Y
5Y
1D
Director Noubar Afeyan Reports Disposal of Moderna Inc. Common Shares
Reuters · 9h ago
Evercore ISI Reaffirms Their Hold Rating on Moderna (MRNA)
TipRanks · 10h ago
European Medicines Agency Committee Recommends Authorization of New Moderna Covid-19 Vaccine
Dow Jones · 11h ago
Moderna saus CHMP adopts positive opinion for mNEXSPIKE
TipRanks · 11h ago
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Marketing Authorization Of Moderna's mNEXSPIKE (mRNA-1283), New Covid Vaccine For Individuals Aged 12 Years And Older
Benzinga · 11h ago
Moderna Wins EMA Panel Backing for mNEXSPIKE COVID Vaccine Approval
Reuters · 11h ago
Weekly Report: what happened at MRNA last week (1208-1212)?
Weekly Report · 14h ago
3 Cash-Burning Stocks We Steer Clear Of
Barchart · 23h ago
More
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Webull offers Moderna Inc stock information, including NASDAQ: MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.